empasiprubart

BIOLOGICAL2 trials

Sponsors

argenx

Conditions

CIDPCIDP - Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyneuropathyMMNMultifocal Motor Neuropathy (MMN)

Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

Active, not recruitingNCT06742190

argenxMMN, Multifocal Motor Neuropathy (MMN)

Start: 2024-12-18End: 2029-12-01Updated: 2026-05-20

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

RecruitingNCT06920004

argenxChronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

Start: 2025-08-22End: 2030-09-01Target: 218Updated: 2026-09-17